APhase 1/2a trial of Proxinium in combination with a checkpoint inhibitor for the treatment of late-stage squamous cell carcinoma of the head and neck

Trial Profile

APhase 1/2a trial of Proxinium in combination with a checkpoint inhibitor for the treatment of late-stage squamous cell carcinoma of the head and neck

Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Oportuzumab monatox (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Mar 2017 According to an Eleven Biotherapeutics media release, company anticipates initiating this trial in the second half of 2017.
    • 14 Nov 2016 According to an Eleven Biotherapeutics media release, this trial is anticipated to initiate in the first half of 2017.
    • 05 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top